Report Publication Announcement • Dec 11, 2013
Report Publication Announcement
Open in ViewerOpens in native device viewer
PARIS, December 11, 2013 – Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, announced today its schedule for the publication of financial information for 2014.
| Event | Date * |
|---|---|
| 2013 Full-Year Sales | January 8, 2014 |
| 2013 Full-Year Results and 2014 First-Quarter Sales | April 9, 2014 |
| Annual General Meeting | June 11, 2014 |
| 2014 First-Half Sales | July 16, 2014 |
| 2014 First-Half Results | August 28, 2014 |
| 2014 Third-Quarter Sales | October 15, 2014 |
* Subject to modification. Press releases are published after market closes.
Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers highresolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic ducts and lungs and during fine needle aspiration procedures.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com
Mauna Kea Technologies Eric Cohen Vice President, Finance Tel: + 33 1 70 08 09 86 [email protected]
France and Europe Press Relation Madis Phileo - Gilles Dauxerre Tel: +33 (0)6 88 21 59 05 [email protected]
NewCap. Investor Relations and Financial Communication Pierre Laurent / Florent Alba Tel: +33(0)1 44 71 94 94 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.